|
Status |
Public on Dec 06, 2023 |
Title |
Next Generation Sequencing Facilitates Quantitative Analysis of tumor samples from HCC patients receiving Nivolumab. |
Organism |
Homo sapiens |
Experiment type |
Expression profiling by high throughput sequencing
|
Summary |
To identify critical tumor-secreting factors that may contribute to immunotherapy efficacy against HCC, we subjected tumor samples from 10 HCC patients to whole-transcriptome sequencing, and categorized the patients into two groups according to clinical response to nivolumab. We then performed gene expression profiling analysis using data obtained from RNA-seq of Nivolumab reponders and non-reponsers.
|
|
|
Overall design |
Comparative gene expression profiling analysis of RNA-seq data for Nivolumab reponders and non-reponsers.
|
|
|
Contributor(s) |
Liu C, Zhou C, Hung M |
Citation(s) |
38307859 |
|
Submission date |
Oct 07, 2022 |
Last update date |
Feb 15, 2024 |
Contact name |
Chunxiao Liu |
E-mail(s) |
liuchunxiao_1989@126.com
|
Phone |
5713763441
|
Organization name |
MD Anderson Cancer center
|
Street address |
6565 MD Anderson Blvd., Zayed building. Z11.4000A
|
City |
HOUSTON |
State/province |
Texas |
ZIP/Postal code |
77030 |
Country |
USA |
|
|
Platforms (1) |
GPL11154 |
Illumina HiSeq 2000 (Homo sapiens) |
|
Samples (10)
|
|
This SubSeries is part of SuperSeries: |
GSE215013 |
Tumor samples from HCC patients receiving Nivolumab; THP-1 cells under different stimulas. |
|
Relations |
BioProject |
PRJNA906102 |